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Strengths and limitations of this study
 ► This is a feasibility trial of a novel intervention which 
employs an integrated approach for tracking arm 
activity and coaching with the aim of increasing 
stroke survivors’ confidence and ability to use their 
impaired arm in daily activities, increasing the op-
portunities for repetitive rehabilitation (repeating a 
movement or series of movements with a rehabilita-
tive or functional aim).
 ► Patient and public involvement (PPI) with more than 
100 stroke survivors, carers and clinicians have 
contributed to our needs- finding phase, codesigned 
OnTrack and informed the feasibility study. A new 
PPI group will oversee the running of the study and 
help with interpretation of qualitative and quantita-
tive data findings.
 ► An independent process evaluation will provide 
detailed information about implementation, context 
and the mechanisms of impact of the intervention. 
Findings will help in the understanding of interven-
tion fidelity and training needs required for a defin-
itive trial.
 ► For pragmatic reasons, the study uses a non- 
randomised design carried out at a single site—this 
will limit understanding about randomisation and 
recruitment.
 ► Participants will not be followed up after intervention 
period; however, participant views will be sought re-
garding appropriate follow- up times in a subsequent 
definitive trial.
AbStrACt
Introduction Arm weakness is a common problem after 
stroke (affecting 450 000 people in the UK) leading to 
loss of independence. Repetitive activity is critical for 
recovery but research shows people struggle with knowing 
what or how much to do, and keeping track of progress. 
Working with more than 100 therapists (occupational 
therapists and physiotherapists) and patients with stroke, 
we codeveloped the OnTrack intervention—consisting of 
software for smart devices and coaching support—that 
has the potential to address this problem. This is a protocol 
to assess the feasibility of OnTrack for evaluation in a 
randomised control trial.
Methods and analysis A mixed- method, single- arm 
study design will be used to evaluate the feasibility of 
OnTrack for hospital and community use. A minimum 
sample of 12 participants from a stroke unit will be 
involved in the study for 14 weeks. During week 1, 8 
and 14 participants will complete assessments relating 
to their arm function, arm impairment and activation. 
During weeks 2–13, participants will use OnTrack to track 
their arm movement in real time, receive motivational 
messages and face- to- face sessions to address problems, 
gain feedback on activity and receive self- management 
skills coaching. All equipment will be loaned to study 
participants. A parallel process evaluation will be 
conducted to assess the intervention’s fidelity, dose and 
reach, using a mixed- method approach. A public and 
patient involvement group will oversee the study and help 
with interpretation and dissemination of qualitative and 
quantitative data findings.
Ethics and dissemination Ethical approval granted by 
the National Health Service Health Research Authority, 
Health and Care Research Wales, and the London—Surrey 
Research Ethics Committee (ref. 19/LO/0881). Trial results 
will be submitted for publication in peer review journals, 
presented at international conferences and disseminated 
among stroke communities. The results of this trial will 
inform development of a definitive trial.
trial registration number NCT03944486.
IntroduCtIon
Every year around the world over 15 million 
people experience a stroke, leaving 5 million 
people with a permanent disability.1 Stroke 
is the leading cause of disability in the UK; 
half of the nearly 1.2 million stroke survivors 
who live in the country have some form of 
disability, significantly contributing to the 
loss of independence and feeling of isolation 
that they experience.2 3 Furthermore, stroke 
is estimated to cost UK society £26 billion 
every year, with the vast majority of these costs 
borne by the informal care sector.2
Upper limb (arm) weakness is the main 
cause of physical impairment affecting 75% 
of disabled stroke survivors; this equates to 
around 450 000 people in the UK.2 Dose- 
intensive repetitive rehabilitation is widely 
accepted as the ‘gold- standard’ for regaining 
ability after stroke; however, National Health 
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Table 1 Outcome measures
Concept Assessment Week of administration
Patient activation/engagement Patient Activation Measure 1, 8, 14
Arm impairment Fugl- Meyer Assessment for Upper Extremity 1, 8, 14
Arm function Upper Extremity Motor Activity Log-14 1, 8, 14
Gross level of disability modified Rankin Scale 1, 8, 14
Arm pain Visual Analogue Scale 1, 8, 14
Cognitive impairment Montreal Cognitive Assessment 1, 8, 14
Arm neglect Albert’s Test 1, 8, 14
Quality of life EQ- 5D- 5L 1, 8, 14
Arm function Lap- to- Table 1, 8, 14
Service experience Friends and Family Test 8 to 14
System usability System Usability Scale 14
Service (NHS) resources are often limited and unable to 
provide this.4 A recent Cochrane review of over 500 trials 
failed to yield high- quality practice recommendations 
for interventions for the upper limb.5 Arm recovery after 
stroke is a national research priority.6 There is a correla-
tion between physical activity after stroke and the ability 
to perform activities of daily living (most of which involve 
the use of the arm).7 Despite this evidence, studies suggest 
that the actual time patients are active is minimal.8 Many 
current approaches to increasing repetitive rehabilitation 
focus on improving the prescribed rehabilitation sessions 
(typically lasting 45–60 min), often by employing gamifi-
cation techniques.9 10
While this is important, there is untapped potential 
to increase repetitive rehabilitation by targeting the 
large proportion of the day where patients are going 
about their daily activities and can use their arm move-
ment (however small) to a greater extent. Capacity 
for activity could be increased further by using self- 
management methods as demonstrated by several 
different programmes in stroke and other long- term 
conditions.11–14 This has informed the development 
of OnTrack which aims to increase opportunities for 
activity by improving individuals’ self- management 
skills through tailored support and real- time activity 
feedback on their arm movement.
An unpublished ethnographic study conducted by the 
Helix Centre (funded by Innovate UK) confirmed what 
other studies have shown7 8 15 that patients struggle to 
see and keep track of improvements; this impacts their 
motivation and leaves them dependent on therapists for 
feedback. Stroke survivors often report feeling unsup-
ported after leaving hospital and not knowing how to 
best help themselves improve their arm function.16–18 
Feedback gathered from over 100 stroke survivors and 
clinicians was the basis for developing the OnTrack 
intervention.
A proof- of- concept test of OnTrack gathered data 
from a small group of patients (n=7) and confirmed 
that the intervention was safe and generally users 
could understand how and when to use it. Participants 
reported that they were more aware of their impaired 
arm and had increased confidence in using it for new 
tasks. A 20% mean increase in minutes of activity on the 
impaired arm was observed. The work conducted to date 
is unpublished and has some limitations; however, it 
has shaped the intervention and suggests that OnTrack 
has the potential to be a scalable solution that requires 
minimal training and could be used in conjunction 
with NHS services to help increase the overall amount 
of activity performed with the impaired arm. This 
study will assess the feasibility of the OnTrack interven-
tion and inform the design of a definitive randomised 
controlled trial (RCT) to evaluate its clinical effective-
ness, and follows the Standard Protocol Items: Recom-
mendations for Interventional Trials guidelines.19
MEthodS And AnAlySIS
Aims and objectives
The primary aim is to evaluate the feasibility of an RCT 
to test the effectiveness of the OnTrack intervention for 
upper limb rehabilitation after stroke.
The objectives are to:
 ► Assess the feasibility of recruitment from hyperacute 
and acute stroke units, and rehabilitation wards to 
ascertain strategy and recruitment rates.
 ► Assess dropout rates by observing adherence and 
compliance with the intervention.
 ► Understand the acceptability and usability of the 
intervention by stroke survivors.
 ► Understand the acceptability of study procedures by 
healthcare professionals.
 ► Explore implementation fidelity, dose and reach of 
the OnTrack intervention.
The study will also collect clinical outcomes regarding 
arm function, impairment and activation to identify an 
appropriate primary outcome, and to estimate parame-
ters for a sample size calculation for an RCT (table 1).
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Figure 1 Trial diagram. NHS, National Health Service.
Study design
A feasibility study with a nested process evaluation 
(figure 1). The study is a single- site, non- randomised 
intervention trial. The design of the study was developed 
through a collaborative approach between the study 
researchers, a public and patient involvement (PPI) 
steering group, front- line therapists and the Research 
Design Service at the National Institute for Health 
Research.
An independent process evaluation will be conducted 
in parallel to learn about usage and engagement mecha-
nisms of participants, therapists and other frontline staff, 
providing critical information for implementation fidelity 
and impact mechanisms necessary for scale- up.
Study setting
The study will be conducted at an inner city NHS hospital 
Trust in London. Recruited participants will be able to 
continue to receive the intervention at home if discharged 
from hospital prior to ending the intervention period (14 
weeks).
Participants
The inclusion criteria encompasses:
 ► Adults (aged 18 or over).
 ► Stroke diagnosis less than 6 months previously (first or 
recurrent). Some participants will be recruited from 
an in- patient rehabilitation ward, hence the 6- month 
poststroke limit.
 ► Arm impairment of any type or level (including 
weakness—including dense hemiplegia, neglect and 
sensory deficits). This enables better understanding 
of which impairment level groups could benefit or not 
from using the intervention, especially considering 
the impact it may have on people’s motivation regard-
less of their level of impairment.
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 ► Ability to provide informed consent.
 ► Reliability to communicate (verbally or non- verbally) 
and understand English.
 ► Ability to read a predefined short message.
Potential participants who at the time of recruitment 
(or during participation) present with any of the following 
will be excluded:
 ► Unstable medical condition.
 ► Self- reported ‘severe’ pain in the arm affected either 
at rest or during movement.
 ► Severe oedema in the arm affected by their stroke, 
judged by the consenting therapist.
 ► Known discharge plans to a hospital other than the site 
Trust or residential care in less than 7 weeks (a small 
proportion of patients staying at Clinical Neuroreha-
bilitation Unit (CNRU) may be in hospital for up to 
12 weeks).
 ► Participants who are unable to engage with the inter-
vention for a period of more than 7 consecutive days 
will be reviewed in a case- by- case basis by the members 
of the team responsible for delivering the interven-
tion to determine if study continuation is appropriate.
recruitment
Participants will be recruited from the Hyperacute Stroke 
Unit (HASU), Acute Stroke Unit (ASU) and CNRU at an 
inner city NHS Hospital Trust in London.
Stroke therapists (occupational therapists, physio-
therapists) will be responsible for screening and identi-
fying suitable patients. They will introduce the study to 
potential participants and provide information docu-
ments. Potential participants will be given a minimum of 
24 hours to consider the advantages and disadvantages 
of participating in the study and to formulate questions. 
Therapists will be able to answer questions or will liaise 
with the research team to provide an answer. Once all 
questions are answered and a potential participant is 
willing to participate, consent will be taken by the thera-
pist. Only at this stage will patient information be shared 
with the research team. There may be situations where a 
therapist is only able to take verbal consent from a partic-
ipant due to time or material constraints; in such cases, 
the researchers will be able to take written consent from 
the participant on first meeting them.
Sample size calculation
Guidelines advocate a sample size of 12–30 participants 
for feasibility studies.20 Experienced clinical academics 
and clinicians at the trial site have advised to expect 
about 50% of eligible patients to agree to participation 
and a 50% completion rate. This has informed a recruit-
ment plan to identify at least 60 potential participants in 
a period of 30 weeks to reach the minimum sample size.
Intervention
The intervention is the OnTrack system as a whole. The 
system consists of smart devices (smartphone and smart-
watch), software (OnTrack app) and coaching support. 
Smart devices are used to track arm movement. Moti-
vational messages and a real- time display of completed 
arm activity (in minutes) are presented to the user via 
the OnTrack app. Coaching support is provided through 
fortnightly consultations by the researchers. During 
consultations, participants will receive self- management 
training informed by the Bridges Self- Management21 
and Taking Charge After Stroke22 self- management 
programmes. Coaching sessions are themed around 
principles of self- management (see table 2, OnTrack 
consultation column).
Data gathered by the OnTrack system can be accessed 
by the researchers via a digital dashboard to inform 
consultations.
Participants will be loaned all equipment necessary for 
the trial and no previous experience with using smart 
devices is required to participate. Technical support will 
be provided only in cases where the hardware and/or 
software fail to perform the required functions to deliver 
the intervention.
Table 2 provides a participation schedule and a 
summary of the intervention procedures.
outcomes
Feasibility of trial design and procedures
 ► Recruitment strategy and rates (feasibility of recruit-
ment from HASU, ASU and CNRU wards)—percentage 
of patients: screened, eligible, approached, consented 
and excluded after screening. Participants consented 
and recruited will be logged by the research team in 
DOCUMAS.23
 ► Compliance and adherence to intervention—measure 
of minutes of activity per participant as recorded by 
the OnTrack app, engagement with OnTrack app as 
measured by system analytics (eg, compliance with 
starting tracking arm activity daily, number of times 
and times of the day a particular screen is visited, the 
number of messages read and replied to, etc).
 ► Completion rates—percentage of participants who 
complete the 14- week intervention period (not drop-
ping out or being withdrawn from the study).
 ► Acceptability and reasons for decline/withdrawal—
number of participants who withdraw or decline 
the intervention and reasons why. A record of 
reasons for withdrawal and declining will be kept 
by the researchers. Reasons will be categorised in 
order of most common; this information will help 
the research team to understand the reasons why 
someone might drop out or decline to participate 
in the study.
Clinical assessments
As a secondary objective, clinical outcomes will be 
collected at different time points by a qualified member 
of the research team to identify an appropriate primary 
outcome, and to estimate parameters for a sample size 
calculation for an RCT (table 1). The outcome measures 
and assessments are listed next.
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Patient activation
Patient activation is a concept recognised by the NHS that 
describes the knowledge, skills and confidence a person 
has in managing their own health and healthcare.24 This 
will be measured using the Patient Activation Measure 
(PAM)25 which has been validated in stroke populations 
in the UK.26 The PAM survey measures patients on a 0–100 
scale and can categorise patients into one of four acti-
vation levels along an empirically derived continuum.25 
Activation levels will be used to allocate participants one 
of three different OnTrack coaching tiers. The tiers aim 
to make the different aspects of the coaching more rele-
vant and meaningful for the individual participant and 
their stage of recovery and self- management.
Arm impairment
Arm impairment will be measured objectively using the 
Fugl- Meyer Assessment for Upper Extremity (FMA- UE).27 
The FMA- UE has been tested extensively and is found 
to have excellent psychometric properties and is recom-
mended as core measures to be used in every stroke 
recovery and rehabilitation trial.28
Arm function
Arm function will be assessed using the Upper Extremity 
Motor Activity Log-14 (MAL).29 The MAL is a scripted, 
structured interview developed to self- report the amount 
and quality of use of the impaired arm in individuals with 
stroke in 14 different activities of daily living.
Gross level of disability
The modified Rankin Scale30 is the most prevalent func-
tional outcome measure in contemporary stroke trials. 
The mRS quantifies disability using an ordinal hier-
archical grading from 0 (no symptoms) to 5 (severe 
disability).
Arm pain
Pain will be assessed using a Visual Analogue Scale (VAS) 
from 0 (no pain) to 10 (excruciating pain) over the last 
24 hours. VAS is a valid measure of pain intensity and is 
responsive to change.31 Individuals scoring 3/10 or more 
in the affected arm will be withdrawn from the study 
unless their pain is only on movements that are not part 
of their usual everyday activities (eg, arm pain when doing 
overhead reaching).
Cognitive impairment
Cognitive impairment will be assessed using the Montreal 
Cognitive Assessment (MoCA). The MoCA is a brief cogni-
tive screening tool with high sensitivity and specificity 
for detecting mild cognitive impairment.32 The MoCA 
defines impairment as follows: score of 18–25=mild, 
10–17=moderate and <10 = severe.32 Participants’ scores 
will be used to look for associations between the use of 
OnTrack and any cognitive impairment.
Perceptual neglect
Albert’s Test is being used to assess for unilateral spatial 
neglect (USN). This a simple test where participants are 
asked to cross out lines ruled in a standard fashion on a 
sheet of paper. If any lines are left uncrossed, and more 
than 70% of uncrossed lines are on the same side as motor 
deficit, USN is indicated. This may be quantified in terms 
of the percentage of lines left uncrossed. The test is very 
easy to administer and is a good predictor of functional 
activity 6 months after stroke onset.33
Quality of life
The EQ- 5D- 5L is a widely used standardised preference- 
based measure of health status developed by the EuroQol 
Group in order to provide a simple, generic measure of 
health for clinical and economic appraisal.34
Additional assessments
A Lap- to- Table timed test will be performed where the 
researchers measure the time it takes a participant to 
move their hand three times from resting on their lap to 
a table positioned in front of them. This test is performed 
to assess its potential to use as part of the inclusion criteria 
for an RCT.
The NHS Friends and Family Test35 will be used to obtain 
feedback on the overall experience of using OnTrack 
and participating in the trial. Participants will be asked: 
‘How likely are you to recommend OnTrack to friends 
and family if they needed similar care or treatment?’ with 
answers provided in a Likert 5- point scale ranging from 
‘extremely likely’ to ‘extremely unlikely’ and an ‘I don’t 
know’ option.
The System Usability Scale (SUS) will be used to subjec-
tively assess the usability of the OnTrack intervention. The 
test is a simple, 10- item scale covering a variety of aspects 
of system usability, such as the need for support, training 
and complexity, and thus have a high level of face validity 
for measuring the usability of a system.36
Process evaluation
A process evaluation will be carried out by researchers 
working independently to the intervention team and in 
parallel to the trial to determine whether the OnTrack 
intervention was delivered as intended and to under-
stand the mechanisms of impact. The aim of the process 
evaluation at the feasibility stage is mainly to understand 
how the trial design and intervention could be optimised 
ahead of an RCT.37 A logic model38 39 that defines the 
intervention in terms of inputs, outputs, causal assump-
tions and expected outcomes has been developed to help 
identify core questions for the evaluation team to explore 
(figure 2). The evaluation team will observe 10% of all 
intervention sessions with the objective of documenting 
fidelity, dose and reach of the intervention.
Critical reflection and the process evaluation will help 
refine the intervention, as shown by mid- range theories 
(ie, theories that help understand implementation).40 
Interim results will be shared with the intervention team 
at the half- way point with the objective to review some of 
the procedures and make minor adjustments as necessary.
 o
n
 April 3, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034936 on 23 March 2020. Downloaded from 
7Fusari G, et al. BMJ Open 2020;10:e034936. doi:10.1136/bmjopen-2019-034936
Open access
Figure 2 Logic model.
In- depth semistructured interviews will be conducted 
with patients at the end of their participation; a minimum 
sample of 12 is anticipated. A topic guide with themes 
drawing from the logic model will be used. Interviews will 
focus on participants’ experiences using OnTrack, their 
perceptions of arm tracking, motivational messaging 
and the researcher consultations. Additionally, the inter-
views will explore participants’ perceptions of the impact 
OnTrack had on them in terms of progress, awareness, 
participation and confidence in self- management. Partic-
ipants’ responses will be compared against activity data 
collected from the OnTrack app.
NHS therapists caring for participants taking part will 
be consented and invited to complete a short online 
survey to gather their feedback regarding acceptability 
of study procedures and they have the option to respond 
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anonymously. The total number of therapists involved is 
difficult to predict as there may be team changes and staff 
movement during the course of the study. The survey will 
ask questions around three themes: (1) participation, 
relevance, quality and time spent in study procedures; (2) 
opinions on the benefit/detriment OnTrack may have for 
patients and (3) opinions on how the intervention may 
or may not fit with service provision and their workflow.
data analysis
Analysis will be completed on the parameters and imple-
mentation of the study in addition to the usability of 
OnTrack.
Data collected for the process evaluation will be a 
combination of qualitative data from interviews with 
participants who had a stroke and therapists to explore 
their experiences of using OnTrack, as well as quantita-
tive data on the usage of OnTrack and the self- reported 
SUS. OnTrack therapy support sessions will be moni-
tored through a fidelity checklist and observations (10 
live sessions will be observed in total). In addition, the 
evaluation team will have access to recorded sessions that 
can be observed at their discretion). Interview data will 
undergo thematic analysis by the evaluation team. Data 
will be entered into NVIVO41; line- by- line coding and 
analysis will be informed by Braun and Clark’s approach 
to thematic analysis.42
Changes over time will be evaluated in both OnTrack 
usage and outcome measures.
For OnTrack usage, the team will analyse users’ activity 
patterns by day and hour of day. Figure 3 illustrates 
examples of visualisations created using aggregated data 
captured by OnTrack from healthy beta testers between 
June and August 2019. It compares users on active 
minutes per hour of day (aggregated over time) and 
active minutes per day.
OnTrack also captures specific usage metrics, including:
 ► Number of times OnTrack messages were opened.
 ► Number of times daily and weekly activity were viewed 
on the phone.
 ► Number of swipes on watch to reveal activity graph.
For each patient, we will plot the values above against 
their minutes of activity to better understand the poten-
tial impact of the app on activity over time.
The self- reported PAM will be captured at weeks 1, 8 
and 14 for each user. It will be analysed in relation to the 
minutes of activity of each user over time to better under-
stand the potential impact of the app on their levels of 
activation. SUS will be captured at weeks 8 and 14 and 
will be compared against actual usage metrics (described 
above) to assess usability.
While conducting meaningful significant subgroup 
analyses would be difficult given the relatively small 
sample size, we believe that outputs from this study could 
potentially inform the subgroups that might be consid-
ered for inclusion in a larger trial.
All data will be stored and accessed in accordance with 
General Data Protection Regulation (GDPR) guidance.
Clinical trial support will be provided by the Big Data 
and Analytical Unit at Imperial College London’s Insti-
tute of Global Health Innovation.
PAtIEnt And PublIC InvolvEMEnt
To date, over 100 stroke survivors, carers and therapists 
have been involved in the design of OnTrack. Partici-
pants have been instrumental in highlighting areas for 
improvement in upper limb stroke rehabilitation. They 
have contributed to a codesign process (including work-
shops, interviews, observations and surveys) resulting in 
the design, development and initial testing of OnTrack.
A steering group comprising four stroke survivors was 
formed for the purpose of this feasibility study. Diversity 
within the group—both in terms of demographics and 
stroke severity—was considered. The group has super-
vised the development of all patient- facing material 
ensuring its clarity. They will also participate in data anal-
ysis by helping to refine themes and key messages arising 
from qualitative interviews. Participants will be trained by 
experienced researchers for this purpose.
The steering group will meet five times over the dura-
tion of the study, including an initial briefing session at 
the start to outline their involvement. Steering group 
members will be key members of the research team and 
their time and travel will be reimbursed according to 
the National Institute for Health Research INVOLVE43 
guidelines.
The PPI involvement plan was shared with Imperial 
College London’s PPI ‘Research Partners Group’ on 21 
February 2019 who felt that the needs of the steering 
group have been accounted for.
EthICS And dISSEMInAtIon
The OnTrack study will be conducted in accordance 
with the recommendations for physicians involved in 
research on human subjects adopted by the 18th World 
Medical Assembly, Helsinki 1964 and later revisions; and 
in compliance with the relevant UK and European legis-
lation including the NHS Health Research Authority 
(HRA) policy frameworks and the GDPR 2018.
The study was granted ethical approval by the HRA, 
Health and Care Research Wales, and the London–Surrey 
Research Ethics Committee (ref. 19/LO/0881). Local 
site capacity and capability approval has been granted by 
the hospital Trust.
The current approved protocol version is V.1.3 dated 
19 June 2019. Protocol amendments will be submitted for 
approval to the NHS HRA in the first instance and to the 
local site thereafter ahead of implementation.
The chief investigator is responsible for preserving the 
confidentiality of participants taking part in the study. 
Researchers will have patients’ names, contact numbers, 
emails and home addresses for the purposes of arranging 
visits. This information will be stored in accordance with 
GDPR legislation. Participants are free to withdraw from 
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Figure 3 Examples of visualisations created using aggregated data captured by OnTrack from healthy beta testers. Data for a 
minimum of 5 and a maximum of 18 days were aggregated for the period between June and August 2019.
the study at any time. However, anonymised activity data 
collected may still be used for data analysis as this is 
unlinked of any patient identifiable information.
The day- to- day management of the study will be coor-
dinated by the Helix Centre. A study steering committee 
formed by the intervention team, evaluation team, PPI 
group and representatives from the local site will meet at 
regular intervals throughout the study.
Regular updates about the trial will be made available 
through social media, blog posts, newsletters and the 
Helix Centre website ( www. helixcentre. com). Trial results 
will be submitted for publication in journals, presented at 
national and international stroke meetings and confer-
ences and disseminated among stroke communities.
trial status
The first participant was enrolled on 9 September 2019 
and recruitment is expected to complete by the end 
of March 2020. Enrolment and data collection were 
continuing as planned at the time of submission of this 
protocol.
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